Association between pan-immune-inflammation value and no-reflow in patients with ST elevation myocardial infarction undergoing percutaneous coronary intervention

Basit Öğe Kaydı
dc.contributor.authorBayramoglu, Adil
dc.contributor.authorHidayet, Siho
dc.date.accessioned2024-08-04T20:54:33Z
dc.date.available2024-08-04T20:54:33Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractNoreflow is a condition associated with a poor prognosis in ST segment elevation myocardial infarction patients. It has been shown that many inflammatory markers and index such as procalcitonin, C-reactive protein, neutrophil to lymphocyte ratio, systemic immune inflammatory index (SII), are associated with noreflow. We used a brand-new index pan-immune-inflammation value (PIV) to retrospectively evaluate the relationship between PIV and noreflow. A total of 1212 patients were included for analysis. Noreflow was observed in 145 patients. In multivariate analysis, PIV (odds ratio (OR): 1.025; [1.002-1.115], p < 0.001), baseline ejection fraction (OR: 0.963; [0.934-0.993], p = 0.015), stent length (OR: 1.032; [1.010-1.054], p = 0.004), age (OR: 1.034; [1.014-1.053], p = 0.001) and pain to PCI time (OR: 1.003 [1.002-1.005], p < 0.001) were observed to be the independent predictors of noreflow. ROC curve analysis showed that the best cut off value of PIV for predicting noreflow was & GE;889 with 77.2% sensitivity and 77.5% specificity (AUC, 0.828; 95% CI [0.806-0.849]). A ROC curve comparison analysis was performed to compare PIV and SII. The predictive power of PIV was higher than SII (differences between areas: 0.154; p < 0.001). According to our findings, an increase in PIV is an independent predictor of noreflow in patients with STEMI.en_US
dc.identifier.doi10.1080/00365513.2023.2241131
dc.identifier.endpage389en_US
dc.identifier.issn0036-5513
dc.identifier.issn1502-7686
dc.identifier.issue6en_US
dc.identifier.pmid37498164en_US
dc.identifier.scopus2-s2.0-85165919594en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage384en_US
dc.identifier.urihttps://doi.org/10.1080/00365513.2023.2241131
dc.identifier.urihttps://hdl.handle.net/11616/101488
dc.identifier.volume83en_US
dc.identifier.wosWOS:001037546500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofScandinavian Journal of Clinical & Laboratory Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPan-Immune-Inflammation valueen_US
dc.subjectnoreflowen_US
dc.subjectST- elevation myocardial infarctionen_US
dc.subjectpercutaneous coronary interventionen_US
dc.subjectsystemic immune inflammatory indexen_US
dc.subject>en_US
dc.titleAssociation between pan-immune-inflammation value and no-reflow in patients with ST elevation myocardial infarction undergoing percutaneous coronary interventionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu